Skip to main content
NewslettersWatchlist

Nektar Therapeutics(NKTR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Nektar Therapeutics Reports Third Quarter 2022 Financial Results

PR Newswire - Thu Nov 3, 2022

SAN FRANCISCO, Nov. 3, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

watchlist
25 stocks most added to Watchlists
market news
At midday: TSX falls as Shopify forecast hammers tech stocks
A trader works on the trading floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 5.
market news
The close: S&P 500 and TSX extend winning streaks, despite Disney drag
A specialist trader works at his post on the floor at the New York Stock Exchange (NYSE) on April 29.
investor newsletter
A change in market leadership may be imminent. Plus, an index-beating U.S. dividend portfolio strategy
Traders work on the floor at the New York Stock Exchange in New York, Wednesday, May 1, 2024. (AP Photo/Seth Wenig)
globe investor
Tensions rise in Silicon Valley over sales of startup stocks
SpaceX logo and Elon Musk silhouette are seen in this illustration taken, December 19, 2022.
inside the market
How pro money managers are balancing exposure to Canadian and U.S. stocks
Rob Carrick
market news
The close: TSX up more than 300 points to three-week high as rate cut hopes renew
Traders work on the floor of the New York Stock Exchange (NYSE) on May 3.
market news
The close: Wall Street sharply higher as nonfarm payrolls report strengthens case for rate cuts in both the U.S. and Canada
A trader works inside a booth on the floor of the New York Stock Exchange on May 1.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).